GSK falls in line with Big Pharma's reaction to Ukraine invasion, cutting off new clinical trials, donating profits and more

Paul Schloesser

Associate Editor

Just a few days after multiple Big Pharmas such as Bayer and Pfizer started the de-facto Big Pharma response to Russian aggression in Ukraine, other …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GSK falls in line with Big Pharma's reaction to Ukraine invasion, cutting off new clinical trials, donating profits and more

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

J&J reports durability data for bladder cancer 'pretzel' drug after FDA filing

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

GSK falls in line with Big Phar­ma's re­ac­tion to Ukraine in­va­sion, cut­ting off new clin­i­cal tri­als, do­nat­ing prof­its and more

Associate Editor

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

GSK falls in line with Big Pharma's reaction to Ukraine invasion, cutting off new clinical trials, donating profits and more